PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

Cell Reports

Volumn 20, Issue 8, 2017, Pages 1818-1829

  Gato Cañas, Maria ^a   Zuazo, Miren ^a   Arasanz, Hugo ^a,b   Ibañez Vea, Maria ^a   Lorenzo, Laura ^a   Fernandez Hinojal, Gonzalo ^a,b   Vera, Ruth ^b   Smerdou, Cristian ^c   Martisova, Eva ^c   Arozarena, Imanol ^a   Wellbrock, Claudia ^d   Llopiz, Diana ^c   Ruiz, Marta ^c   Sarobe, Pablo ^c   Breckpot, Karine ^e   Kochan, Grazyna ^a   Escors, David ^a,f  

^a IdiSNA Navarra Institute for Health Research   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B7 H1; CD274; immunotherapy; interferon; PD L1; PD1; PDL1; signal transduction

Indexed keywords

BETA 2 MICROGLOBULIN; CASPASE 7; JANUS KINASE 1; JANUS KINASE 2; PROGRAMMED DEATH 1 LIGAND 1; STAT3 PROTEIN; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; INTERFERON;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION INITIATION; ANIMAL; C57BL MOUSE; FEMALE; HEK293 CELL LINE; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; B7-H1 ANTIGEN; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; INTERFERONS; MICE; MICE, INBRED C57BL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85028320126     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.07.075     Document Type: Article

References (33)

1. Apelbaum, A., Yarden, G., Warszawski, S., Harari, D., Schreiber, G., Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol. Cell. Biol. 33 (2013), 800–814.
2. Azuma, T., Yao, S., Zhu, G., Flies, A.S., Flies, S.J., Chen, L., B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111 (2008), 3635–3643.
3. Broos, K., Keyaerts, M., Lecocq, Q., Renmans, D., Nguyen, T., Escors, D., Liston, A., Raes, G., Breckpot, K., Devoogdt, N., Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget 8 (2017), 41932–41946.
4. Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., Freeman, G.J., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27 (2007), 111–122.
5. Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
6. Clark, C.A., Gupta, H.B., Sareddy, G., Pandeswara, S., Lao, S., Yuan, B., Drerup, J.M., Padron, A., Conejo-Garcia, J., Murthy, K., et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76 (2016), 6964–6974.
7. Corpet, F., Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16 (1988), 10881–10890.
8. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
9. Escors, D., Ortego, J., Laude, H., Enjuanes, L., The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability. J. Virol. 75 (2001), 1312–1324.
10. Escors, D., Lopes, L., Lin, R., Hiscott, J., Akira, S., Davis, R.J., Collins, M.K., Targeting dendritic cell signaling to regulate the response to immunization. Blood 111 (2008), 3050–3061.
11. Fife, B.T., Pauken, K.E., Eagar, T.N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M.F., Bluestone, J.A., Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10 (2009), 1185–1192.
12. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000), 1027–1034.
13. George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524 (2015), 47–53.
14. Hodi, F.S., Hwu, W.J., Kefford, R., Weber, J.S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T.C., et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34 (2016), 1510–1517.
15. Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C.L., Collins, M., Escors, D., PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 3 (2011), 581–592.
16. Katlinskaya, Y.V., Katlinski, K.V., Yu, Q., Ortiz, A., Beiting, D.P., Brice, A., Davar, D., Sanders, C., Kirkwood, J.M., Rui, H., et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. 15 (2016), 171–180.
17. Lanna, A., Henson, S.M., Escors, D., Akbar, A.N., The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat. Immunol. 15 (2014), 965–972.
18. Liechtenstein, T., Perez-Janices, N., Blanco-Luquin, I., Goyvaerts, C., Schwarze, J., Dufait, I., Lanna, A., Ridder, M., Guerrero-Setas, D., Breckpot, K., Escors, D., Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. OncoImmunology, 3, 2014, e945378.
19. Liechtenstein, T., Perez-Janices, N., Gato, M., Caliendo, F., Kochan, G., Blanco-Luquin, I., Van der Jeught, K., Arce, F., Guerrero-Setas, D., Fernandez-Irigoyen, J., et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget 5 (2014), 7843–7857.
20. Lim, S.O., Li, C.W., Xia, W., Cha, J.H., Chan, L.C., Wu, Y., Chang, S.S., Lin, W.C., Hsu, J.M., Hsu, Y.H., et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30 (2016), 925–939.
21. Radivojac, P., Vacic, V., Haynes, C., Cocklin, R.R., Mohan, A., Heyen, J.W., Goebl, M.G., Iakoucheva, L.M., Identification, analysis, and prediction of protein ubiquitination sites. Proteins 78 (2010), 365–380.
22. Ragimbeau, J., Dondi, E., Alcover, A., Eid, P., Uzé, G., Pellegrini, S., The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 22 (2003), 537–547.
23. Selden, C., Mellor, N., Rees, M., Laurson, J., Kirwan, M., Escors, D., Collins, M., Hodgson, H., Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J. Gene Med. 9 (2007), 67–76.
24. Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Ribas, A., Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168 (2017), 707–723.
25. Sharpe, A.H., Wherry, E.J., Ahmed, R., Freeman, G.J., The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8 (2007), 239–245.
26. Shin, D.S., Zaretsky, J.M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C.S., Hugo, W., Sandoval, S., Torrejon, D.Y., et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7 (2017), 188–201.
27. Smyth, M.J., Type I interferon and cancer immunoediting. Nat. Immunol. 6 (2005), 646–648.
28. Van der Jeught, K., Joe, P.T., Bialkowski, L., Heirman, C., Daszkiewicz, L., Liechtenstein, T., Escors, D., Thielemans, K., Breckpot, K., Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget 5 (2014), 10100–10113.
29. Vannucchi, S., Percario, Z.A., Chiantore, M.V., Matarrese, P., Chelbi-Alix, M.K., Fagioli, M., Pelicci, P.G., Malorni, W., Fiorucci, G., Romeo, G., Affabris, E., Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells. Oncogene 19 (2000), 5041–5053.
30. Yu, Q., Katlinskaya, Y.V., Carbone, C.J., Zhao, B., Katlinski, K.V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep. 11 (2015), 785–797.
31. Zak, K.M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., Holak, T.A., Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23 (2015), 2341–2348.
32. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
33. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.